Literature DB >> 6334451

Emergency distal splenorenal shunts for variceal hemorrhage refractory to nonoperative control.

J R Potts, J M Henderson, W J Millikan, W D Warren.   

Abstract

Two points are emphasized by this report. First, every attempt should be made to control acute variceal hemorrhage nonoperatively. Such control can be gained in about 80 percent of patients, allowing for a period of stabilization of liver disease, correction of coagulation defects, and nutritional repletion. Operative mortality then becomes equivalent to that in other elective candidates. Second, when necessary, because of ongoing hemorrhage in the face of maximal nonoperative therapy, selective shunting can be accomplished on an emergency basis. In our study, it resulted in a 70 percent survival rate and excellent protection against recurrent variceal hemorrhage with long-term maintenance of portal perfusion in 89 percent of the patients.

Entities:  

Mesh:

Year:  1984        PMID: 6334451     DOI: 10.1016/0002-9610(84)90444-6

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  4 in total

1.  Appraisal of distal splenorenal shunt in the treatment of esophageal varices: an analysis of prophylactic, emergency, and elective shunts.

Authors:  N Nagasue; H Kohno; Y Ogawa; H Yukaya; R Tamada; Y Sasaki; Y C Chang; T Nakamura
Journal:  World J Surg       Date:  1989 Jan-Feb       Impact factor: 3.352

Review 2.  Role of distal splenorenal shunt for long-term management of variceal bleeding.

Authors:  J M Henderson
Journal:  World J Surg       Date:  1994 Mar-Apr       Impact factor: 3.352

Review 3.  Surgical management of acute variceal hemorrhage.

Authors:  L F Rikkers; G Jin
Journal:  World J Surg       Date:  1994 Mar-Apr       Impact factor: 3.352

4.  Clinical results of the transjugular intrahepatic portosystemic shunt (TIPS) for the treatment of variceal bleeding.

Authors:  S W Han; Y E Joo; H S Kim; S K Choi; J S Rew; J K Kim; S J Kim
Journal:  Korean J Intern Med       Date:  2000-12       Impact factor: 2.884

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.